Co-Diagnostics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $622,489 | $3.9M | $6.8M | $34.2M | $97.9M |
| Cost of revenue | $222,377 | $999,124 | $4.2M | $5.5M | $11.6M |
| Gross profit | $400,112 | $2.9M | $2.6M | $28.7M | $86.3M |
| Research and development | $19.1M | $21.0M | $23.0M | $17.4M | $15.0M |
| Operating expenses | $50.6M | $43.0M | $45.3M | $55.7M | $40.2M |
| Operating income | -$50.2M | -$40.1M | -$42.7M | -$27.0M | $46.1M |
| Pretax income | -$48.5M | -$37.6M | -$38.1M | -$18.8M | $45.6M |
| Income tax expense | -$1.6M | $57,368 | -$2.8M | -$4.6M | $9.0M |
| Net income | -$46.9M | -$37.6M | -$35.3M | -$14.2M | $36.7M |
| Balance Sheet | |||||
| Cash and equivalents | $11.9M | $2.9M | $14.9M | $23.0M | $88.6M |
| Current assets | $13.7M | $32.3M | $62.1M | $92.7M | $115.1M |
| Total assets | $24.7M | $63.6M | $95.3M | $123.1M | $160.0M |
| Current liabilities | $3.5M | $7.3M | $5.7M | $3.9M | $12.6M |
| Total liabilities | $4.1M | $9.7M | $9.3M | $8.6M | $25.6M |
| Stockholders' equity | $20.6M | $53.9M | $85.6M | $114.5M | $134.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$29.1M | -$29.2M | -$22.1M | $6.6M | $41.1M |
| Depreciation and amortization | $1.1M | $1.4M | $1.2M | $1.3M | $335,363 |
| Stock-based compensation | $2.2M | $5.4M | $8.3M | $7.5M | $5.5M |
| Capital expenditure | $700,047 | $748,352 | $1.4M | $1.4M | $669,463 |
| Free cash flow | -$29.8M | -$29.9M | -$23.4M | $5.1M | $40.4M |
| Share repurchases | — | — | $1.4M | $14.2M | — |
| Impairments | $18.9M | — | $0 | $15.4M | — |
Shares outstanding 3.6M · Free float 34.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.